Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis

Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Key Stats

• Today's Range: $0.29 to $0.31
• 50-Day Range: $0.29 to $0.70
• 52-Week Range: $0.27 to $1.57
• Volume: 203,612 shs
• Average Volume: 2.27 million shs
• Market Capitalization: $1.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Quoin Pharmaceuticals Stock Analysis - MarketRank™

Quoin Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Quoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Quoin Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quoin Pharmaceuticals are expected to grow in the coming year, from ($2.05) to ($2.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quoin Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quoin Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quoin Pharmaceuticals has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

55.11% of the float of Quoin Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quoin Pharmaceuticals has recently increased by 5,936.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quoin Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Quoin Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

55.11% of the float of Quoin Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quoin Pharmaceuticals has recently increased by 5,936.04%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.12

News Sentiment

Quoin Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Quoin Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Quoin Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Quoin Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Quoin Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.

QNRX Stock Analysis - Frequently Asked Questions

How have QNRX shares performed this year?

Quoin Pharmaceuticals' stock was trading at $0.6507 at the start of the year. Since then, QNRX stock has decreased by 54.4% and is now trading at $0.2970.
View the best growth stocks for 2025 here.

How were Quoin Pharmaceuticals' earnings last quarter?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) posted its earnings results on Thursday, November, 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.03.

When did Quoin Pharmaceuticals' stock split?

Quoin Pharmaceuticals shares reverse split on the morning of Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Who are Quoin Pharmaceuticals' major shareholders?

Top institutional investors of Quoin Pharmaceuticals include Altium Capital Management LLC (5.59%), Renaissance Technologies LLC (2.64%), Boothbay Fund Management LLC (1.60%) and Apollon Wealth Management LLC (1.58%). Insiders that own company stock include Denise P Carter, Gordon Dunn, Anthony James Culverwell and Michael Myers.
View institutional ownership trends.

How do I buy shares of Quoin Pharmaceuticals?

Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Quoin Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Bank of America (BAC), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Zomedica (ZOM) and Abbott Laboratories (ABT).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 3/12/2025
• Next Earnings (Estimated): 3/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:QNRX
• CIK: 1671502
• Web: quoinpharma.com
• Phone: (703) 980-4182
• Fax: 972-9767-8750
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +1,220.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,690,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -125.60%
• Return on Assets: -64.77%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.02
• Quick Ratio: 3.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.74 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 5,050,000
• Free Float: 4,863,000
• Market Cap: $1.53 million
• Optionable: Not Optionable
• Beta: 1.82